See what’s new.
Gene therapy developed at Duke to be commercialized by a local biotechnology company
A universal gene editing therapy for Pompe disease, invented in the lab of Duke Professor Dwight Koeberl, is licensed for further development by local start-up GeneVentiv.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.
Breath of Life: Duke Inventors Secure $5M for Novel Oxygenation Startup
Duke clinician partners with Duke engineers to tackle an elusive critical care challenge: Can oxygen be delivered directly into the bloodstream through a catheter?
Colleagues off the Court: Duke and UNC Champion Research and Innovation on Capitol Hill
From Google’s search to 3D printing, from MRIs to mRNA vaccines, countless products and services that make our lives better started as university born innovations from research.
Durham agtech startup Avalo secures $11M in funding
Avalo is a Duke agtech start-up based on technology developed by former postdoc Mariano Alvarez (Biology, Trinity) and Professor Cynthia Rudin (CS, Trinity).
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Lumotive Raises $45 Million to Expand Sales of Programmable Optical Semiconductors
Lumotive is a metamaterials start-up spun out of the labs of Professor David Smith and Associate Professor Maiken Mikkelsen (ECE, Pratt). Mikkelsen's former postdoc Gleb Akselrod is the founder and CTO.
Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies
DMC Technologies is a Duke start-up commercializing sustainable chemistry technology out of the lab of Associate Professor Michael Lynch (BME, Pratt).